Safety of OFS Combined With AI Endocrine Therapy in Chinese Premenopausal Breast Cancer Patients

NCT02440230 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

110

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: OFS + Anastrozole
DRUG: OFS + Exemestane

Sponsor

Shanghai Jiao Tong University School of Medicine